|
Photo Gallery | About Us | Terms of Use | Register/Create a Profile |
"The United States Food and Drug Administration classifies Cannabidiol as a schedule one drug, even though it doesn’t induce euphoria or an altered state of mind; whereas, Canada has classified it as a schedule 2 drug. On April 19, 2005 Health Canada approved Sativex and allowed it to be prescribed for Multiple Sclerosis and cancer pain. Sativex is the world’s first pharmaceutical medicine derived from the cannabis plant. One spray of Sativex contains a fixed dose of 2.7 Mg THC and 2.5 Mg CBD. As of right now the FDA has approved Sativex for clinical trials in the study of patients with advanced cancers."
FAIR USE NOTICE: This site may at times contain copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. If you wish to use copyrighted material from this site for purposes of your own that go beyond 'fair use', you must obtain permission from the copyright owner. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml |